<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/FF466B46-A9B2-48B8-A58C-62539B3F8D3E"><gtr:id>FF466B46-A9B2-48B8-A58C-62539B3F8D3E</gtr:id><gtr:name>Exhalation Technology Ltd</gtr:name><gtr:address><gtr:line1>WATERFALL HOUSE WORTHING ROAD , SWANTON MORLEY</gtr:line1><gtr:city>DEREHAM</gtr:city><gtr:postCode>NR20 4QD</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF466B46-A9B2-48B8-A58C-62539B3F8D3E" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>FF466B46-A9B2-48B8-A58C-62539B3F8D3E</gtr:id><gtr:name>Exhalation Technology Ltd</gtr:name><gtr:address><gtr:line1>WATERFALL HOUSE WORTHING ROAD , SWANTON MORLEY</gtr:line1><gtr:city>DEREHAM</gtr:city><gtr:postCode>NR20 4QD</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>50182.0</gtr:offerGrant><gtr:projectCost>84518.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9759EFE2-4635-4A39-95B6-D7292BD30306"><gtr:id>9759EFE2-4635-4A39-95B6-D7292BD30306</gtr:id><gtr:firstName>Oliver</gtr:firstName><gtr:surname>Diggle</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710467"><gtr:id>38FB2303-2087-4249-806D-78AE31451B79</gtr:id><gtr:title>Home monitoring device for self-monitoring and control of COPD exacerbations</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710467</gtr:grantReference><gtr:abstractText>We propose to develop a small, fully automatic, user-friendly device to detect lung
inflammation to be used
at home by COPD (Chronic Obstructive Pulmonary Disease) patients themselves. The device
will use exhaled breath with H2O2 as the marker. It will allow COPD patients to share the
results with healthcare staff remotely and make it easier for people from COPD risk groups to
be screened.
Current diagnosis and monitoring of COPD are typically based on clinical examination,
spirometery, forced expiratory volumes and lung capacity measurements. A few commercial
devices for detection of NO (Nitric Oxide) in exhaled breath exist, but NO detection generally
requires a controlled exhalation, making it unsuitable for most COPD patients and for
selfmonitoring. In the UK, there are estimated to be 6 million COPD sufferers, but the
European COPD Coalition states that only an estimated 900,000 (1.5% of the population of
the UK) are correctly diagnosed.The cost to the NHS of COPD prescriptions and hospital
admissions in 2010 was &amp;pound;578 million (NICE Costing Report 2011). We estimate that cost
savings of 10% of this would be achievable after 18 months if our device was adopted. As
exhaled H2O2 does not require a controlled exhalation, H202 is an ideal marker for home
monitoring of COPD. We have successfully demonstrated real-time assessment of lung
inflammation using exhaled H202 in clinical settings in a pilot study at the UEA Medical
School. The study demonstrated that exhaled breath H202 measurement can be applied to
provide exact real-time analysis, and confirmed that exacerbating COPD patients display
significantly higher H2O2 values.Patients found H202 sampling easy and preferable to
alternative solutions, especially during exacerbations, where breathlessness made spirometry
and NO measurements difficult.By developing the concept into an &amp;quot;all in one&amp;quot; fully automatic
smaller device we will enable patients and physicians to detect lung inflammation far earlier.</gtr:abstractText><gtr:fund><gtr:end>2014-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>50182</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710467</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>